跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-05AI 评分29

Epicrispr 更新 EPI-321 治疗 FSHD 数据,继续显示令人鼓舞结果

Epicrispr builds case for FSHD treatment with updated data for EPI-321

AI 导读

Epicrispr 公布 EPI-321 治疗面肩肱型肌营养不良症(FSHD)的更新数据,继续显示令人鼓舞的试验结果。EPI-321 是一种表观遗传编辑疗法,针对这一遗传性肌肉疾病,更新数据涉及 12 人。

正文

Epi­crispr Biotech­nolo­gies con­tin­ued to show en­cour­ag­ing find­ings from test­ing of its epi­ge­net­ic edit­ing treat­ment for the ge­net­ic mus­cle dis­ease fa­cioscapu­lo­humer­al mus­cu­lar dy­s­tro­phy.

Twelve peo­ple have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news